Johnson & Johnson to acquire Halda Therapeutics for $3.05B, sees dilution

Johnson & Johnson announced that it has entered into a definitive agreement to acquire Halda Therapeutics for $3.05B in cash. The transaction is expected to close within the next few months, subject to antitrust clearance and other customary closing conditions. The lead candidate, HLD-0915, is a clinical-stage therapy for prostate cancer. Under the terms of the agreement, Johnson & Johnson will acquire Halda. The transaction will be accounted for as a business combination and is expected to close within the next few months, subject to antitrust clearance and other customary closing conditions. The company expects dilution in 2026 of 15c to adjusted EPS due to short-term financing and a non-recurring charge related to the equity awards for Halda employees upon closing. Johnson & Johnson will provide commentary on full year 2026 guidance during the fourth quarter earnings call on Wednesday, January 21, 2026.